Old drug, new hope: atovaquone tested against tough ovarian cancer

NCT ID NCT05998135

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase II trial tests whether atovaquone, a drug currently used to treat certain infections, can help control platinum-resistant ovarian cancer. The study enrolls 28 patients whose cancer has progressed within six months of their last platinum-based chemotherapy. Participants will take atovaquone by mouth and undergo regular scans and biopsies to see if the drug slows tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atovaquone
What this could lead to: If it works, this could offer a new treatment option for ovarian cancer that has stopped responding to standard platinum chemotherapy.
What could go wrong: This is a small, early-phase trial with only 28 participants. The drug is being tested for a new purpose, so it may not work against cancer, and side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian carcinoma ovarian serous adenocarcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA PLATINUM-RESISTANT OVARIAN CARCINOMA

Contacts and locations

Locations

Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.